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studed, all of them showed c h c a l  alterations, cytologd changes, 
both or partners with lesions. The samples were taken by sterilized 
swabs (Viratype. Digene). For PCR, oligonucleotides primers MY09 
and MY011 were used, which recognize L1 viral region. The viral 
typhcation was achieved by using Sharp S+ detection system 
(Digene), which recognizes virus of low oncogenical risk 6, 11,42, 
43, 44; intermednte/high oncogenical risk: 16, 18, 31, 33, 35, 45, 
51,52, 53, 56, and 58. 
Results: In the 66.6% (80/120) of patients was observed the 
presence of the viral genome and 33.3% (40/120) of the patients 
were negative for HPV (p < 0.0001). In the subgroup of patients 
with no morfological changes, it was found viral DNA in 40% of 
the samples, h m  which 23.3% showed HPV high risk type (HR), 
3.3% oflow risk (LR) and 13.3% were not typified. In patients with 
Low Grade Intraepithelial Lesions (LSIL) was found HPV in 70% of 
the samples (HR = 56.6%, LR = 3.75% and Not typified = 15%). 
In the subgroup wth High Grade Intraepithelial Lesions (HSIL) was 
observed the presence of HPV in the 80% of all samples (HR = 50% 
and Not Tpified = 30%). 
[ PI138 1 Detection of Human Papillomavitus (HPV) in 
Genital Lesions 
C. Bicho', C. Ornelas2, L. Rosado', A. Pacheco', I. Cabral'. 'S. 
Gynaecology, Instituto Porfugu& de Onrologia, Lisbon, Portugal, 'Lab. 
Virology Instituto Portugu& de Oncologia, Lisbon, Portugal 
Introduction: Specific HPV types are associated with the develop- 
ment of genital lesions. Amongst these, some HPV types (16, 18, 
31, 33 and 54) are smngly associated with cervical carcinoma (zur 
Hausen 1989). 
Objective: To study the incidence of HPV High-Intermediate 
Rsk  (HR) and Low Risk (LR) in genital lesions, by hybrid capture 
system. 
Patients and Methods: Flfty clinical specimens of cervix (biop- 
sies or scrapes) of women with an average (33 f 9.9) years old, were 
grouped as follows: group 1 (n = 12), Koilocytosis; group 2 (n = 
12), Cervical Intraepitheld Neoplasia (CIN I); group 3 (n = 13) 
CIN 11-111; group 4 (n = 13). Epidermoid Carcinoma. 
HPV DNA detection was made through a chemilumines- 
cent molecular hybriduation method with concensus probes 
for Low Risk (6/11/42/43/44) and I-&$-Intermediate Risk 
(16/18/31/33/35/45/51/52/56). Group 4 was hybridized with in- 
dividual probes (HPV 16 and HPV 18) with crossreactivity control. 
(1) group 1 - 6/12 (50%) were positive for HPV W.R) type and 
(2) group 2 - 8/12 (67%) were positive for HPV (H.R) type and 
(3) group 3 - 9/43 (70%) were positive for HPV (H.R) type and 
(4) group 4 - 13/13 (100%) were positive for HPV W.K) type 
Results: The results in Werent patient groups were: 
4/12 (33.3%) we& positive for HPV (L.R) type 
2/12 (16.6%) were positive for HPV 6.R) type 
2/13 (15.3%) were positive for HPV (LR) type 
In the group 4, the use of individual probes showed that: 
6/13 (46%) were HPV 16 positive and 3/13 (23%) were HPV 18 
Conclusion: These results suggest that there is a correlation be- 
positive 
tween High-Risk HPV infection and aggressive types of lesion. 
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I PI1 39 I Comparative In L4?m Activity of Trovafloxacin 
Against Fresh Bacterial Isolates from Pediatric 
Patients 
D. Adam. Department ofAnfimicrobial Therapy and InfeC'ous 
Immunology, Children'z Hospital, University $Munich, Germany 
Trodoxacin (TRO) is a novel fluomnapthyridone antibiotic. In 
comparison with fluoroquinolones, TKO has an enhanced activity 
against Gram-positive and anaerobic pathogens. It &plays favourable 
pharmacokinetic properties, enabling once-daily administration. 
In this study, the in viho activities of TRO in comparison with 
ciprofloxacin (CIP), imipenem (MI), and ceftazihe (CTAZ) were 
determined against 495 k s h  bacterial isolates h m  pediatric patients. 
Standard microdilution techniques with Mueller-Hinton broth or 
Standard-1 broth #7882, Merck (indicated with *) were used. MICSO 
and MIGO d u e s  for the most commonly isolated pathogens were: 
n TRO CIP IMI CTAZ 
50%/% 50%/9056 50%/90?? 5 w / m  
S. pncumonim 26 0.12/0.12 0.03/1 1/2 0.25/0.5 
E. f d i s  32 0.12/1 0.511 1/2 32/32 
E. f k u m  28 1/8 32/32 4/32 32/32 
s. , l u m  52 0.03/0.03 0.25/0.25 0.03/0.12 818 
S. epidmnidir 52 0.03/2 0.12/16 0.25/32 32/32 
I? cmug'nosl? 50 0.25/0.5 0.2511 0.5/2 214 
E. mli 56 0.03/0.03 0.003/0.03 0.12/0.25 0.2514 
EnfmbMn spp. 34 0.03/0.12 0.12/0.25 0.06/0.25 0.5132 
K. pnrumoddr 30 0.03/0.5 0.12/0.25 0.03/0.25 0.12/32 
I? mimbilu 30 0.2V0.25 2/2 0.03/4 0.03/0.06 
H .  inJu-m' 31 0.03/0.03 0.03/0.5 0.2511 0.12/0.12 
TRO was the most active antibiotic against Gram-positive 
pathogens. Agamt Gram-negative pathogens, TRO was as accive 
as CIP and IMI, and more active than CTAZ. 
I PI140 1 Trovafloxacin: In Vim Anti-Anaerobic Act iV i  
Including Spectrum, Bactericidal Activity, and 
Mutational Frequency 
K.E. Aldridge, D. Ashcraft, K.A. Bowman, R. Carlson. Louisiana 
State University Medical Center, New Orleans, Louisiana, USA 
Currently marketed fluoroquinolones including ciprofloxacin and 
ofloxacin have wide-spectrum activity against aerobic gram-negative 
bacilli but poor activity against clinically important anaerobes. 
Trovafloxacin is a new azabicyclo-naphthyridone with an expanded 
spec- against aerobes. 
Objectives: To compare the activity of trovafloxacin and other 
antimicrobials against various clinically important anaerobes. 
Methods: A total of 590 clinical isolates of anaerobes fiom various 
sources were tested using an NCCLS recommended broth microdi- 
lution procedure. 
Results: Trovafloxacin was highly active against all species wth  
a mode MIC of 0.25 wg/ml, an MIC90 of 1 bg/ml, and inhibited 
97% of the B. jiagilis group at 2 pg/ml. Trodoxacin had com- 
parable activity to metronidazole and was 8- to 64-fold more active 
than ampicillin/sulbactam, clindamycin, ciprofloxacin, cefoxitin, and 
cefotetan overall includtng strains of Clostridium, Fusobacterium, Por- 
phyromonas, and Prevotella. Bactericidal activity of trodoxacin was 
concentration-dependent and showed progressive bactericidal activ- 
ity against the B. Jragilis group at 4x and 8x MIC over 24 hr. The 
mutational frequency of B.jagi2is s n a i n s  to mdoxacin was <lo7 
at 8 x  and 12x MIC. Little effect on trovafloxacin was noted at 
different pHs, inoculum sizes, and increased protein concentrations. 
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Conclusions: These data indicate that mdoxac in  may be po- 
tentially useful in mixed aerobiclanaerobic mfections. 
I PI141 1 Susceptibility of Selected Bacteria Against 
Tmvafloxacin and Cipmfloxacin as Determined 
Using the E-test 
R. Neuburger, P Santanam, I. Perschil, EH. Kayser, M. Altwegg. 
Deparfment of Medical Microbiology, University of Zurich, Swifzerland 
Using the E-test, we have compared minimum inhibitory concen- 
trations (MICs, mg/L) of trodoxacin (TKO), Ciprofloxacin (CIP) 
and, in part, Cefeiaxone (CRO) against methicillin-resistant Staphy- 
lococcus aureus ( M R S A  N = 190), Streptocorns pneumoniae (N = 332), 
Enterobarteri'aceae infkquently encountered in dinical specimens (N 
= 213), and diarrheagenic organisms (N = 179) including entero- 
toxigenic &TEC), verotoxigenic (VTEC) and enteroinvasive E .  coli 
(EIEC), Aeromonus, Campylobarter, Salmonella, Shigella and Yminia 
species. 
Against MRSA, MIC50/MIC90 were 1.5/232 for CIF', 
0.094/>32 for TRO, and ?256/>256 for CRO. With S. pneu- 
moniae the respective values were 0.75/1.5 for CIF', 0.125/0.19 for 
TRO, and 0.016/0.032 for CRO. The percentage of s t r a i n s  suscep- 
tible against TRO (u&ed/proposed breakpoints were 5 2  mg/l for 
susceptibility and z 8  mg/l for resistance), CIP and CRO was 100, 
87.3 and 98.2 for S. pneumoniae and 77.4, 48.9 and 37.9 for MRSA, 
respectively. 
All Gram-negative bacteria (including 10 erythromycin-resistant 
Campylobacter jejudcoli) were fully susceptible agatnst both TRO 
(range _(0.002-1.5) and CIP (range 50.0024.38) with MICi being 
slightly lower for CIP than for TRO. 
Conclusion: TKO is more active than CIP against the 
Gram-positive bacteria and comparable to or slightly less active than 
CIP against the Gram-negative organisms tested. 
I PI142 1 Comparative In Vtm Activities of Trovafloxacin 
and 16 Other Antibiotics Against Penicillin 
Intermediate (PEP) and Penicillin Resistant 
(PRSP) Streptococcus pneumoniae Isolates 
L. Saravolatz I ,  0. Manzor I ,  J. Pawlak '. 'St. john Hospital, Dehoit, 
MI, U S A ,  'Henry Ford Hospital, Detroit, MI, USA 
The activity of Trovafloxacin was compared to 16 other antibiotics 
against 43 consecutive isolates (18 PRSP and 25 PISP). Minimal in- 
hibitory concentrations were evaluated by microbroth dilution using 
Mueller Hinton Broth supplemented by 3% Lysed Horse Blood. 
MICw 
PISP PRSP PISP PRSP 
Trovafloucin 0.25 0.25 Cefotaxirne 0.5 1 
Winafloxann 0.06 c0.03 Ccfnzodme 8 16 
1 16 64 Spadoxadn 2 Ccfundme 
Pelucillin 1 16 Cefmme 16 64 
Impenem 1 1 Cefpodonme 2 8 
Meropenern 2 8 Rarnopknin 0.25 0.25 
Synercid 0.5 1 Tetchoplm 0.5 0.13 
Vancomycin 1 0.5 
Ciprofloxacin 4 2 C e fu i ax o n c 0.5 2 
Many antibiotics demonstrate good in vitro activity yet substan- 
tial differences can be observed within the same class of antimi- 
croblal agents. For the quinolones Clinafloxacin > Trodaxcin > 
SparRoxacin > Ciprofloxacin. In view of achievable serum levels 
Trodoxacin and Clinafloxacin should be considered for clinical 
trials of Streptococcus pneumoniae including PISP and PRSP 
I PI143 I Susceptibility of Selected Bacteria Against 
Tmvafloxacin and Ciprofloxacin as Determined 
Using the E-test 
R. Neuburger, P Santanam, I. Perschil, EH. Kayser, M. Altwegg. 
Department of Medical Microbiology, University qf Zurich, Switzerland 
Using the E-test, we compared minimum inhibitory concentrations 
(MICs, mgA) of trodoxacin (T'RO), ciprofloxacin (CIP) and, in 
part, cefeiaxone (CRO) against rnethdlin-resistant Staphylocorcuc 
nureus (MRSA; N = 190). Streptocorcuc pneumoniae (N = 332), En- 
terobacteriaceae idrequently encountered in clinical specimens (N 
= 213), and diarrheagenic organisms (N = 179) including entero- 
toxigenic (ETEC), verotoxigenic (VTEC) and enteroinvasive E.  coli 
FIEC), Aeromonus, Campylobacter, Salmonella, Shigella and Yersinia 
species. 
Agatnst MRSA, MICC,O/MIC~O were 0.094/>32 mg/l for TRO, 
1.5/>32 mg/l for CIF', and >256/>256 mg/l for CKO. For S. 
pneumoniae, the respective values were 0.125/0.19 mg/l for TRO, 
0.75A.5 mg/l for CIF', and 0.016/0.032 mg/l for CRO. The per- 
centages of s t r a i n s  susceptible against TKO (utilized/proposed break- 
points were t 2  mg/l for susceptibility and > 8  mg/l for resistance), 
CIP and CRO were loo%, 87.3 and 98.2% for S. pneurnoniae, and 
77.4%. 48.9% and 37.9% for MRSA, respectively. 
All Gram-negative bacteria (including 10 erythromycin-resistant 
Campylobacter jguni/coli] were fuly susceptible to both TRO 
(t0.002-1.5 mg/l) and CIP (t0.0024.38 mg/l) with MICs be- 
ing slightly lower for CIP than for TRO. 
Conclusion: TRO is more active that CIP against Gram-positive 
bacteria and comparable to, or slightly less active than, CIP against 
Gram-negative organisms tested. 
Comparative In Vim Activities of Tmvafloxacin 
S.P. Tiengrim, N. Aswapokee, B. Charoensook, K. Sangsiriwut. 
Siriraj Hospital, Mahidol University, Bangkok, Thailand 
Objective: To study the in vitro antibacterial activities of 
trodoxacin, a new fluoronaphilidine quinolone and compare them 
with other quinolones and relevant comparative agents. 
Methods: A total of 655 recent clitllcal isolates were tested for 
minimum inhibitory concentrations (MICs) by standard agar dilution 
techque  (NCCLS) or E-test (AB Biodisk) with 17 antimicrobial 
agents. 
Results: For gram-positive cocci; S. aureus (MSSA), entero- 
cocci, PSSP and PRSF', the MICso of trovafloxacin, o5oxacin and 
ciprofloxacin were 0.025-0.25, 0.5-4 and 0.5-2 pg/ml, respec- 
tively. Trodoxacin's MICs were 6-20 times lower than ofloxacin 
and ciprofloxacin. The MICs of trodoxacin agatnst gram-negdtive 
cocci, N. gononhoeae (F'PNG and NPPNG) were similar to those 
of ofloxacin and ciprofloxacin (0.00254.01 pg/ml). For gh- 
cose-fermenting gram-negative bacilli, includmg E .  coli, K. pneu- 
moniae and Enterobacter spp., the MICso of trovafloxacin, ofloxacin, 
ciprofloxacin and amikacin were 0.014.025,0.054.25,0.025-0.05 
and 2-4 pg/ml, respectively. Trodoxacin's MICs were almost equal 
to cipro5oxacin's against most species of the Enterobarteri'aceae, ex- 
cept against Morganella, Proreus and Providem'u, trovafloxacin's MICs 
were higher than ciprofloxcain's. For non-fermenters, the MICSO 
of tmdoxacin, ofloxacin, ciprofloxacin, amikacin and ceftavdime 
were 0.05-2, 0.25-8, 0.5-8, 4-64 and 2-32 pg/ml. Within the 
group of non-fermenten, A. baumannii was the most susceptible 
(MIC50 = 0.05 pg/ml) and B. p seudode i  was the most resistant 
(MICso = 2 pg/ml). 
Conclusions: Trodoxacin showed good activities against both 
gram-positive and gram-negative bacteria. Trodoxacin extened its 
spectrum to cover S. aureus (MSSA), S. pneumoniae (PSSP and PRSP) 
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and enterococci except for MRSA when standard agents was clearly 
superior. Trodoxacin exert good inhinsic potency (MIC50) against 
glucose-fermenting gram-negative bacilli, I? amginosa, A .  baumannii 
and S. maltophilia. 
lP1145 I In Vim Activity of Tmvafloxacin and Five Other 
Fluomquinolones 
M.P. Montanari ' , M. Prenna ', M. Mingoia ' , P.E. Varaldo ' , 
S. FLipa'. 'Institute c$Microbiology, Univmity ofdncona, Italy, 
'Department o fMCA Biology, University .f Camerino, Italy 
Objectives: to assess the in vim inhibitory and bactericidal activ- 
ities of trodoxacin and five other fluoroquinolones (ciprofloxacin, 
ofloxacin, pefloxacin, rufloxacin, and, spartloxacin) against a wide 
range of clinical isolates h m  Italian hospitals. 
Methods: MICs (microdilution method) and MBCs were deter- 
mined by standard procedures as recommended by NCCLS. 
Results: Against gram-positive bacteria, trodoxacin was overall 
more active than the other antibiotics tested, including spartloxacin, 
another gram-positive-oriented fluoxuquinolone, and was active 
against all ciprofloxacin-resistant streptococci, enterococci and lis- 
teriae, all ciprofloxacin-resistant Staphylococnrs aureus isolates, and 
most ciprofloxacin-resistant coagulase-negative staphylococci. Its an- 
tistaphylococcal activity was not aflected by oxacilln resistance 
or suxeptibihty of the isolates, nor its antipneumococcal activ- 
ity by whether isolates were susceptible or resistant to penicilln. 
Agamst gram-negative bacteria, m d o x a c i n  retained a high po- 
tency, mostly comparable with that of ciprofloxacin. Rufloxacin and 
pefloxacin were less active than the other fluoroquinolones against 
most test strains of both gram-positive and gram-negative organisms. 
Trovafloxacin MBCs usually equalled or exceeded by 2 to 4 dmes 
the MIC values, indicating that the compound is overall highly bac- 
tericidal. 
Conclusion: In vivo studies and clinical trials with trovafloxacin 
are warranted and strongly urged. 
[p1146] In vitm Activii of Levofloxacin Against Isolates 
from Patients with Community Acquired Lower 
Respiratory Tract Infections 
J.M. Casellas Is2, M. Gilardoni I ,  G. Tom; S. Ivanovic ', 
M. O ~ U M  I ,  A. D o h  3,  M. Ascoli ', J.M. Montero ', 
H. Ariza 5. 'Cenrro de Estudios en Antiminobianos, San Fernando, 
Hospital, Argentina, 'San Lucac, San Isidro, Hospital, Argentina, 
3Cetrangolo, 'c( Lopez, Hospital, Argentina, 4Municipal, S.  Fernando, 
Hospital, Argentina, 'Mi  Pueblo, E Varela, Hospital, Argentina 
We cultured cito-bacteriologically valid sputums, BAL, brush pro- 
tected aspirates, pleural fluid and/or blood h m  69 patients with 
community acquired pneumonia (CAP} and valid sputum &om 154 
patients with acute exacerbations of chronic bronchitis (AECB). Eu- 
bacteria were recovered sigdicatively h m  31 CAP (45%) and 94 
AECB (61%). The four predominant species among CAP were S. 
pneumoniae (Sp) 67%; H. injuenzae (Hi) 13%;MebsielZa spp. (Kp) and 
S. aureus (Sa) 6.5% each and among AECB: Sp 37%; M .  catanhalis 
(Mc) 29; Hi 18 and F? aemginosa (Pa) 10. MICs were determined 
by microdilution or Etest for oral antimicrobials against the 125 
CAP and AECB isolates. Overall susceptibhty (S) percentages were 
for; levofloxacin (LV) 97; ciproiioxacin (CP) 95; ofloxacin (OF) 95; 
azithromycin (AZ) 88; mxithromycin (RO) and darithmmycin (CL) 
87; cefuroxime (FU) 86; amoxicillin-clavulanate (AC) 80 and ce- 
fixhe (FI) 75. We also compared the activity of LV against 60 Sp 
(40 penicillin unsusceptible) LV showed 100% S; OF 92; CP 82; CL 
and RO 96; AZ 94; AC 96; FU 80 and FI 35. We also demostrated 
that LV showed 100% S agaimt 20Mc, 20Hi, 20SAMS and was the 
activiest drug against 20 Kp (95% S) and 20 Pa (92% S). 
Ip11471 /n vitn, Bacteriostatic ~ c t i v i i  of Levofloxacin 
and Three Other Fluoroquinolones against 
Penicillin-Susceptible and Penicillin-Resistant 
Streptococcus pneumoniae 
A. Frhaux, G. Sissla, P. Geslin. sentice de Microbiologie, Cenfre 
National de Rijiirence des Pneumomques, CHI,  94010 Criteil, France 
Worldwide spread of pneumococcal penicillin resistance has led to 
a need for therapeutic alternatives and new quinolones may be use- 
ful for infections caused by resistant pneumococci. The purpose 
of this study was to investigate the susceptibility to levofloxacin 
(LVFX), ofloxacin (OFX), spdoxacin (SPFX) and ciprofloxacin 
(CIP) of 205 strains (101 penicillin-susceptible Ips], 51 peni- 
cillin-intermedate-resistant [PIR], 53 penicillin-resistant PR]) that 
had been sent by French hospitals participating in the National Co- 
operative Survey of Pneumococcal Infections between September 
1996 and October 1996. The determination of MICs (mgfl) was 
made by the agar dilution method. The comparative activities of the 
4 drugs were as follows: 
PS PIR PR 
MIC50 MlCw Range MIC50 MICw Range Mlc50 MICw Rvlgc 
SPFX 0.25 0.5 0.06-0.5 0.25 0.25 0 .060 .5  0.25 0.25 0.124 
CIP 0.5 I 0.25-2 0.5 1 0.12-1 0.5 1 0.25-16 
LVFX I 1 0.25-1 0.5 1 0.25-1 1 1 0.5-16 
OFX 1 2 0.5-2 1 2 0.5-2 1 2 1-32 
A total of 204 of the s t r a i n s  had a LVFX MIC between 0.25 mg/l 
and 1 mg/l and only one of the 205 strains was highly resistant 
(MIC = 16 mgll). Whatever the level of susceptibility to penicillin 
(PS/PIR/PR) the relative bacteriostatic activity for the four drugs 
was: SPFX > CIP > LVFX > OFX. 
Ip11481 Comparative /n vitm ~ c t i v i i  of Levofioxacin 
(LV) Against Isolates from Adult Patients with 
Community-acquired Lower Respiratory Tract 
Infections (CLRTI) 
J.M. Casellas Is', M. GiIardoni ', G. Tom6 
S. Ivanovic', M. Orduna', A. Dolmann', M. Ascoli*, 
J.M. Montero ', H. Ariza 5 .  ' Centro de Estudios en Antiminobianos 
(San Fernando) Hospital, Argentina, 'Sari Lucac (San Isidro) Hospital, 
Argentina, Cerrhngolo (a Ldpez) Hospital, Argentina, 'Municipal (S. 
Fernando) Hospital, Argentina, ' M  Pueblo (E Varcla) Hospital, Argentina 
We cultured bacteriologically-validated sputums, BAL, brush-pro- 
tected aspirates, pleural fluid and/or blood h m  69 patients with 
community-acquired pneumonia (CAP) and bacteriologically-valid- 
ated sputum &om 154 patients with acute exacerbations of chronic 
bronchitis (AECB). 
Sigdcant numbers of Eubacteria were recovered h m  31 CAP 
(45%) and 94 AECB (61%) specimens. The 4 predominant species 
in the CAP specimens were S. pneumoniae spp. (Sp, 67%), H .  inzuen- 
zae (Hi, 13%), K. pneumoniae (Kp, 6.5%) and S. aureus (Sa, 6.5%). 
AECB isolates consisted of Sp (37%). M. catanhalis (Mc, 29%), Hi 
(18%) and I! amginosa (Pa, 10%). MICs were determined by mi- 
crodilution or E-test for oral antimicrobials against the 125 CLRTI 
isolates. The o v e d  susceptibility percentages of the CLRTI iso- 
lates were: LV 97%, ciprofloxacin (CP) 95%. ofloxacin (OF) 95%. 
azithromycin (AZ) 88%, roxithromycin (RO) 87%, clarithromycin 
(CL) 87%, cefuroxime 0 86%, amoxicillin-clavulanate (AC) 80% 
M. Goldberg ' , 
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and cefudme (FI) 75%. We also compared the activity of LV and 
other agents against 60 Sp (of whtch 40 were unsusceptible to peni- 
c h ) .  These isolates showed 100% susceptibility to LV, 92% to OF, 
82% to CP, 96% to CL and RO, 94% to AZ, 96% to AC, 80% to 
FU and 85% to FI. We also demonstrated that 20 Mc, 20 Hi and 
20 mehcillin-susceptible Sa isolates were 100% susceptible to L'iz 
Furthermore, LV was the most effective drug against 20 Kp (95% 
susceptibility) and 20 Pa (92%) isolates. 
1 PI149 I The Bactericidal Activity of Levofloxacin and 
Other Fluoroquinolones against Streptococcus 
pneumoniae 
J. George, I. Morrissey. University of HWtjordshire, Hatfield, England, 
UK 
The emergence of penicillin-resistant (pen-res) Streptococncs pneumo- 
niae (SP) has become a problem over recent years. To overcome this, 
new drugs such as the fluoroquinolones (FLQs) are being consid- 
ered for the treatment of SP infections. In this study, the bacterici- 
dal activity of levoftoxacin (LVFX), ofloxacin (OFX), ciprofloxacin 
(CPFX) and spdoxacin (SPFX) was investigated against 4 strains 
of SP (pen MIC, mg/l): SP C3LN4 (0.0075), SP 269 (0.0075), SP 
1600 (O.l), SP KPR (2). Bactericidal activity was determined against 
SP (at about lo6 CFU/ml) in nutrient broth plus laked horse blood 
(7%) for 3 h at 37°C. The results for SP C3LN4 are shown in Fig. 
1. LVFX was the most bactericidal drug tested against SP C3LN4, 
followed by OFX, CPFX and SPFX, in that order of potency. Simi- 
lar results were obtained with the other strains, including the pen-res 
strain. This suggests that pen-res does not &ect the potency of FLQs 
against SP Therefore, FLQs would be a good option for pen-res SP 
therapy. Of the 4 drugs tested, LVFX would appear to be the FLQ of 
choice against such infections. These findings warrant hrther clinical 
evaluation of LVFX in the treatment of SP mfections. 
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I P1150 I Results of a European Multicentre Study of the 
Comparative In Vitro Susceptibility of 
Gram-negative Bacteria to Levofloxacin 
D. Felmingham MJ. Robbins I, I. Mathias ', K. Ingley ' ,  
H. Bhogal', R.N. Griineberg'. 'CR Micro Ltd., London, UK, 
'University College London Hospitak N H S  Trust, London, UK 
A multicentre study of the comparative susceptibihty of a wide range 
of chically importanc Gram-negative species to levofloxacin was 
undertaken. 3316 isolates (2052 Enterobarteriaceae; 412 Ps. aeruginosa; 
162 H .  injuenzae; 140 M. catanhalis; 186 Neissm'a spp.; 364 others) 
were collected &om 20 European centres during 1993-1994. MICs 
of levofloxacin (LVFX), ofloxacin (OFX), ciprofloxacin (CPFX), 
spdoxacin (SPFX) and nalidixic acid (NAL) were determined us- 
ing the NCCLS agar incorporation method. LVFX was very active 
against species of the Enterobarteriaceae with MIC90 for the major- 
ity of species in the range 0.03-0.5 mgA. The relative potency 
of the four fluoro-quinolones against these isolates was: CPFX > 
LVFX/SPFX > OFX. However, the overall merence between 
the compounds was seldom greater than 2-fold. LVFX showed 
good activity against Ps. aeruginosa with 80% of 412 isolates in- 
hibited by 5 2  mg/l. Agamst this species, LVFX was twice as 
active as OFX/SPFX and 4-fold less active than CPFX. All of 
the fluoroquinolones tested demonstrated potent antibacterial ac- 
tivity against other Gram-negative species including: Haemophilus 
spp., M. catanhalis, Neisseria spp., B. pertussis, L. pneumophila, Vib- 
rio spp., C. jejuni, H .  pylon', A.  hydrophila and I? shigeNoides with 
MIC90 in the range 0.015-0.06 mgA. These results demonstrate 
the broad-spectrum potent antibacterial activity of LVFX against 
Gram-negative species whtch, when considered together with its 
superior pharmacokinetics to CPFX, the most active of the com- 
pounds tested, suggest it will have an important role in the treatment 
of a wide range of lnfections caused by these organisms. 
I PI151 I Serum Bactericidal Activii of Levofloxacin 
PM. Shah. Uniwrsitatsklinikum, Zentmm der Inneren Medizin 
Infektiologie, 040590, Frankfirrt, Federal Republic of Germany 
Objectives: To determine the serum bactericidal activity (SBA) of 
levofloxacin following a single 500 mg oral dose to twelve healthy 
volunteers. 
Methods: Todd-Hewitt-Broth (microdilution method. NCCLS, 
M2-T)  supplemented with lysed horse blood was inoculated with 
13 S. pneumoniae strains (lo5 CFU/ml). >99.9% reduction after an 
over-night incubation was defined as serum bactericidal titre (SBT). 
SBT was calculated by log transformation of each reciprocal bacte- 
ricidal titre, where t l : 2  was handled as 1:l. All experiments were 
repeated twice, Quality conml strains were E. coli ATCC 25922, S. 
aureus ATCC 25923 and S. aureus Oxford 6571. 
Results: 
Table: Duration (h) ofSBA greater that SBT dilution 1:2 
Strun Duraaon Srmn Duntion S t u n  Duration 
33,229** 3.40 6796 4.32 
713 1.33 18,055 0.75 17,077 5.98 
32,475- 6.31 15, 135 6.31 1 6 , W f  3.40 
15,357 5 40 20,224 3.16 40,932* 2.74 
13.904 3.32 
7724 3.57 
* Pemcdhn reuscant, ** Pemlcdhn 2nd Cefotaxlme resistant 
Mean 3.85 h, SD 1.77, CV% 46.1, SEM 0.49, Mm 0.75, Medan 
The mean durahon of SBA for the QC s t r a i n s :  E .  coli >24 h, S. 
3.40, Max 6.31, Range 5.56 
aureus Oxford 10 h and ATCC 10.6 h. 
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Conclusions: Serum levels achieved following 500 mg lev- 
ofloxacin resulted in SBA (SBT >1:2) from 0.75 to 6.3 h, whch 
was independent of sensitivity to penicillin and cefotaxime. 
I PI1 52 I lntracellular Activity of Ciprofloxacin and Bay 
12-8039 
B. Al-Nawas, PM. Shah. Univenitiitsklinikum, Inakfiologie, 0-60.590 
Frankfurt, Germany 
Objectives: The intra- and extracellular activity of Ciprofloxacin 
(CIP) and Bay 12-8039 (BAY) against Staphylococcus aureuc (SA) 
showing various antibiotic susceptibility pattern. 
Methods: Polymorphonudear leukocytes (PMN) and 
pre-opsonised SA (Odord NCTC 6571, ATCC 25923 and 
six MRSA) were incubated at a ratio of 1:l for 15 minutes at 37°C. 
Extracellular bacteria were removed by Merentid centrifugation. 
Phagozytised bacteria were incubated with 0.1, 1, and 10 fold 
MIC. Aliquots were taken during 4 hours and the number of viable 
bacteria (CFU/ml) was determined by subculture technique. 
Results: The MIC ofCIP was 0.5 p g / d  and 216 p g / d  respec- 
tively. The MIC of BAY was 0.063 p g / d  and 2 pg/d respectidy 
The table shows the % of CN/ml without/with PMN after 4 h of 
incubation. 
SA Oxford NCTC 6571 MRSA s e ~ t i v e  MRSA rcsxtant to 
SA ATCC 25923 CO CIP CIP MR-CIP RSA 
0.1 MIC Cip 133 (268) 
I MIC Cip 116 (101) 
IOMICCip 24 (10) 
0.1 MIC Bay 94 (190) 
1 MIC Bay 124 (169) 
10MICBy 66 (40) 
170 (367) 281 (183) 
151 (106) 114 (97) 
15 (10) 89 (86) 
224 (339) 323 (278) 
171 (178) 210 (168) 
39 (5) 43 (2) 
Conclusions: Against test strains and MRSA both BAY and CIP 
were equally active, against MR-CIP-RSA BAY was more cidal 
against extra-and intracellular Staphylocoai. 
I PI1 53 1 Activity of BAY 12-8039 against Gram-Positive 
Cocci 
J.A.A. Hoogkamp-Korstanje. Dept OfMedical Microbiology University 
Hospital St Radboud, Nijmegen, Netherlands 
Objectives: To compare the in vim activity of BAY 12-8039 with 
that of other antibiotics used for infection by gram-positive cocci. 
Methods: 371 gram-positive cocci, blood isolates, were tested 
for their susceptibhty to BAY 12-8039 (BAY), ciprofloxacin (CIP), 
spdoxacin (SPA), m d o x a c i n  (TRO), lomefloxacin &OM), 
levofloxacin (LEV), vancomycin (VAN), teicoplanin (TEI), ery- 
thromycin (ERY), clarithromycin (CLA), imipenem (IMI) and 
meropenem (MER) with microbroth dilution. 
MIC90 fme/L) 
BAY CIP SPA TRO LOM LEV VAN TEI ERY CLA IMI MER 
s. pncu 
s. P P  
MSSA 
MRSA 
S. hem 
MSSE 
MRSE 
E. f e c  
E. fium 
S.  bovis 
s. mit 
0.1 1 0.2 0.1 4 1 0.2 0.1 0.1 0.1 0.1 0.1 
0.1 0.5 0.2 0.1 4 0.5 0.2 0.1 0.1 0.1 0.1 0.1 
0.1 1 0.1 0.1 2 0.2 1 0.5 0.2 0.1 0.1 0.1 
8 32 16 8 32 16 4 1 32 32 16 16 
4 32 32 8 32 16 2 8 32 32 8 16 
0.1 4 0.1 0.1 2 4 2 2 0.1 0.1 0.1 0.2 
2 3 2 1 6 8  32 8 2 4 3 2 3 2 4 8  
16 32 16 16 32 32 2 0.1 32 32 0.5 4 
32 32 32 32 32 32 0.5 0.2 32 32 32 32 
0.2 2 0.5 0.5 16 2 0.2 0.1 32 32 0.1 0.1 
0.2 16 1 0.1 32 4 0.2 0.1 32 32 0.1 '0.5 
Results: The MICs90 of all antibiotics (MIC90) are shown in 
the table. BAY 12-8039 was the most effective quinolone against 
pneumococci, streptococci and methicillin susceptible staphylococci, 
it was not effective against enterococci (only 50% of E. faeralis were 
susceptible), MRSA and S. haemoZyficus. 
Conclusions: Bay 12-8039 shows a promising in vim activity 
and may be a welcome drug in the treatment of pneumococcal and 
streptococcal infections. 
[E] A c t i v i  of BAY 12-8039 against Aerobic and 
J.A.A. Hoogkamp-Kontanje. Dept OfMedical Minobiology University 
Hospital St Radboud, Numefen, Netherlands 
Objectives: To compare the in vim activity of BAY 12-8039 with 
that of other antibiotics used for infection by gram-positive rods. 
Methods: 129 gram-positive rods from clinical materials were 
tested for their susceptibility to BAY 12-8039 (BAY), spdoxacin 
(SPA), mdoxac in  (TRO), chdoxacin (CLF), erythromycin 
(ERY), darithromycin (CLA), chdamycin (DAL), imipenem (IMI), 
meropenem (MFR), augmentin (AUG), p i p e r a h  (PIP) and 
metronidazole (MET) with microbroth dilution. 
Results: The MICs90 of all antibiotics are shown in the table. 
BAY 12-8039 and chafloxacin were the most active quinolones, 
they were the only antibiotics with any activity against Corynebar- 
terium JK. 
Anaerobic Gram-Positive Rods 
MIC90 (mg/L) 
BAY SPA TRO CLF ERY CLA DAL IMI MER AUG PIP MET 
Llstaia 0.5 2 0.1 0.2 0.2 0.1 4 0.1 0.1 0.5 8 - 
CorJK 2 32 16 2 32 32 32 32 32 64 64 - 
Actinomy 0.2 0.5 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.5 32 
Nourdia 8 16 16 2 32 16 32 16 16 64 64 - 
Bifidob 2 4 4 1 0.1 0.1 0.2 0.1 0.1 0.2 0.5 32 
Clortdif 2 4 1 1 1 1 2 0.5 0.2 0.2 1 0.5 
Conclusions: Bay 12-8039 may be an alternative for the treat- 
ment of i ecaons by Listm'a, Aainomyces and Corynebactm'umJK. "f 
The Postantibiotic Effect of BAY 12-8039 
EJ. Boswell, J.M. Andrews, R. Wise. City Hospital N H S  Trust, 
Birmingham, UK 
The postantibiotic effects (PAE) of BAY 12-8039, a new fluo- 
roquinolone on 3 strains of Eschm'chia coli, Staphylococcus aureus, 
Haemophilus injuenzae, Streptococarc pyogenes and Sfqtocoms pneu- 
monia were investigated. BAY 12-8039 solutions were added to log 
phase cultures of approximately lo5 cfu/mL. to give concentrations 
equivalent to 1, 4 and 10 x MIC. Cultures were shaken at 37'C for 
1 h, the BAY 12-8039 concentration was then reduced by 1000-fold 
dilution and incubated at 37'C for 24 h. Viable counts were per- 
formed prior to exposure, hourly for 6 h and at 24 h after dilution. 
Bacteria were enumerated after 24 h incubation at 37°C. PAE was 
defined as PAE = T - C, where T is the time required for the count 
in the test culture to increase 1 log10 above the count observed im- 
mediately after dilution and C is the equivalent time for the control. 
BAY 12-8039 exhibited a si@cant concentration dependent PAE 
with both Gram positive and negative organisms, ranging at 1.4 and 
10 x MIC h m  0 to 2.2 h, 1.2 to 3.1 h and 1.4 to 3.3 h respec- 
tively. BAY 12-8039 exhibited concentration dependent PAE similar 
to that of other fluoroquinolones. 
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I PI1 56 I In vitro Activity of BAY 12-8039 
D. F e h g h a m ' ,  M.J. Robbins', A. Leakey', H. Salman', 
C. Dencer', S. Clark', G.L. Ridgway', R.N. Griineberg'. 'GR 
Micro Lid, London, UK, UCLH N H S  Trust, London, UK 
The in vim activity of BAY 12-8039 (l-cyclopropyl-7 [(S,S)-2,8 
diazabicyclo [4.3.0] non-8-yl]-6-fluoro-8-methoxy-l, 4-dihy- 
dro-4-oxo-3-quinoline carboxylic acid), a new fluoroquinolone, was 
determined against a wide range of clinical bacterial isolates and 
compared with that of ofloxacin. BAY 12-8039 was highly ac- 
tive against all Gram positive species tested being genedy 4-8 
times more active than ofloxacin against fluoroquinolone-susceptible 
(MIC ofloxacin 5 2  mg/L) isolates (MICw [mg/L] Staphylococcus spp. 
0.12, S. pneumoniae 0.12, E.faecalis 0.25 mg/L). BAY 12-8039 was 
also hghly active against isolates of H .  injuenzae (MICw 0.06), M .  
catarrhalis (MIC90 0.12), Neisseria spp. (MIC90 0.03), Legionelh spp. 
(MIC90 0.015), ofloxacin-susceptible isolates of the Enterobacteri- 
aceae (MICso range 0.03-0.5), Campylobacter spp (MIC90 0.5) and 
Mbrio spp. (MIC90 0.25). BAY 12-8039 was somewhat less active 
against isolates of Ps. aemginosa (MIC90 2). BAY 12-8039 was very 
active against M .  pneumoniue (MIC90 0.12), M. hominis (MICgo 0.06), 
U urealyticum (MIC90 0.06), C. trachomatis (MIC90 0.12), C. pneumo- 
niae (MIC90 0.12) and M .  tuberculosis (MIC90 0.25). BAY 12-8039 
was also active against obligate anaerobes including B. jagilis, Pre- 
votella melaninogenica and Fusobacten'um spp. (all 1) and against 
Peptostreptococcus spp. (MIC90 0.25). C. pe&ngens (MIC90 0.5) and 
C. d&le (MICw 1). These results demonstrate the broad spectrum 
antibacterial potency of BAY 12-8039 whlch includes, in particu- 
lar, Gram positive bacteria and a wide range of pathogens of the 
respiratory tract. 
I PI157 I Susceptibility of Anaerobic Bacteria to BAY 
12-8039, a New Fluoroquinolone 
C.E. Nord, C. Edlund. Huddinge University Hospital, Karolinska 
Institute, Stockholm, Sweden 
Objectives: The aim of the present investigation was to determine 
the in vitro activity of BAY 12-8039 compared with other antimi- 
crobial agents against anaerobic bacteria. 
Methods: The activity of BAY 12-8039 was determined against 
360 c h c a l  isolates of anaerobic bacteria by the agar dllution 
method and were compared with levofloxacin, mvafloxack, ce- 
foxitin, imipenem, dindamycin and memnidazole. 
Results: BAY 12-8039 and imipenem were the most ac- 
tive agents tested. Anaerobic cocci (50 strains) had the follow- 
ing minimum inhibitory concentrations: BAY 12-8039, range 
0.125-1.0 mg/l; imipenem, range 0.016-0.064 mg/l. Propionibac- 
terium acne5 (30 strains): BAY 12-8039, 0.064-0.5 mg/l; imipenem, 
0.032-0.064 mg/l. Clostridium perfringens (30 strains): BAY 12-8039, 
0.25-1.0 mg/l; imipenem, 0.0164.5 mgA. Clostridium d@le (50 
stra ins) :  BAY 12-8039, 1.0-2.0 mgA; imipenem, 4.0-8.0 mgA. 
Buteroides jagilis (50 strains): BAY 12-8039, 0.125-1.0 mg/l; 
imipenem, 0.064-0.25 mgA. Bacteroides, Potphyromonas and Prwotella 
species (100 strains): BAY 12-8039, 0.1254.25 mgfl; imipenem, 
0.0164.25 mg/l. Fusobacteria (50 strains): BAY 12-8039, 0.25-1.0 
mg/l; imipenem, 0.008-0.064 mgA. 
Conclusions: BAY 12-8039 may be useful as treatment and pro- 
phylaxis for infections due to anaerobic bacteria. 
Macrolides, streptogramins and 
miscellaneous antibiotics 
m/ In-Viio Pharmacodynamic Parameters 
Describing Efficacy of Quinupristin/Dalfopnstin 
Against Multiple Bacterial Pathogens 
0. Vesga, W.A. Craig. VA Hospital and Uniwsity of Wisconsin, 
Madison, W, USA 
The neumpenic mouse thigh-infection model was used to de- 
termine the pharmacokinetic/pharmacodynamic (PWPD) param- 
eter best describing antimicrobial activity of the new streptogramin 
RP59500 (RP). RP is a combination of two semi-synthetic pristi- 
namycin derivatives, quinupristin (Q) and dalfopristin @), which 
displays strong synergistic effect agaimt gram-positive organisms, in- 
cluding those resistant to known antibiotics. Finding the PK/PD 
parameters predicting efficacy is important because Q, D, and RP 
MICs exhibit wide variation and do not reflect in-vivo response. 
Mice were infected with 4 strains of methich-susceptible (2 
MSSA) and -resistant (2 MRSA) S. aureu and 11 s t r a i n s  of peni- 
cillin-susceptible (1 PSSP), -intermediate (4 PISP), and -resistant 
(6 PRSP) S. pneumoniae. Both MRSA, 3 PISP and 4 PRSP were 
erythromycin-resistant. Mice had 7.04 f 0.65 loglo CFU/Thigh 
when treated for 24 h with RP 2.5-1280 mg/Kg divided into 2 or 
4 doses. A sigmoid dose-response model was used to estimate, by 
non-linear regression, the dose required to produce a net bacterio- 
static effect over 24 h (static dose) and the correlation of PWPD 
parameters with in vivo efficacy of RP. Stepwise regression analy- 
sis was used to estimate the PWPD parameter best predicting static 
dose of RP. Q MIC, but not D MIC or RF' MIC, predicted static 
dose of R P  (R' = 91, 0.4, and 20%, respectively). Of all parameters, 
RP AUC/MIC + Q AUC/MIC exhibited the greatest correlation 
with eficacy (Rz = 67%). Q, D, and RP AUC/MIC ratios, alone 
(Rz = 43. 30, and 62%, respectively) or in any other combination, 
do not reflect the eficacy of RP as well as the addition of FU' + Q 
ratios. 
F1 Antipneurnococcal Activity of RP59500 
(Quinupnstin/Dalfopnstin) as Determined by 
MIC and Time-Kill-Curves 
R.R. Reinert ', S. Simic ', M. Kresken ', R. Liimcken '. 'Institute 
of Medical MicrobioloB, University Hospital of Aachen, Germany, 
'RhBne-Poulenc Rorer, Cologne, Germany 
Objectives: Determination of the antipneumococcal activity of 
the first injectable streptogramin combination -59500 (quin- 
upristin/dalfopristin) by MIC and time-kill-curves. 
Methods: The in vim activity of RP59500 against a group of 93 
pneumococcal isolates fiom systemic infections was determined by 
the standard agar dution method according to the recommendations 
of the National Committee of Clinical Laboratory Standards. 
Results: Of the isolates, 32 were penich-sensitive (Pen-S) and 
erythromycin (Ery-S), 30 erythromycin-resistant (Ery-R) and Pen-S, 
and 31 were penicillin-intermediate (Pen-I) and Ery-S. Against the 
first group of strains (Pen-S, Ery-S) RP59500 showed good ac- 
tivity (MIC90 = 0.5 mg/L). Similar results were obtained for the 
Pen-I Ery-S p u p  of the strains (MIC90 = 0.5 mg/l). Ery-R 
s t r a i n s  were slightly less susceptible (MIC90 = 1 mg/l). Time kill 
testing of 3 Ery-S ckndamycin-susceptible (Ch-S), 3 Ery-R clin- 
damycin-resistant, and 3 Ery-R Ch-S  strains were performed at 0, 
1, 2, and 4 h. RP59500 yielded rapid Iallmg. 
Conclusions: In view of the good activity against all pneumo- 
cocci tested, including Pen-I and Ery-R isolates, -59500 might 
